These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Zamò A; Gerhard-Hartmann E; Ott G; Anagnostopoulos I; Scott DW; Rosenwald A; Rauert-Wunderlich H Virchows Arch; 2022 Dec; 481(6):935-943. PubMed ID: 36219238 [TBL] [Abstract][Full Text] [Related]
46. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Coutinho R; Clear AJ; Owen A; Wilson A; Matthews J; Lee A; Alvarez R; Gomes da Silva M; Cabeçadas J; Calaminici M; Gribben JG Clin Cancer Res; 2013 Dec; 19(24):6686-95. PubMed ID: 24122791 [TBL] [Abstract][Full Text] [Related]
48. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505 [TBL] [Abstract][Full Text] [Related]
49. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453 [TBL] [Abstract][Full Text] [Related]
50. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles. Zhao S; Dong X; Shen W; Ye Z; Xiang R Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285 [TBL] [Abstract][Full Text] [Related]
51. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215 [TBL] [Abstract][Full Text] [Related]
52. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
53. Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations. Guo Y; Takeuchi I; Karnan S; Miyata T; Ohshima K; Seto M Cancer Sci; 2014 Apr; 105(4):481-9. PubMed ID: 24843885 [TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. Hallas C; Preukschas M; Tiemann M Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939 [TBL] [Abstract][Full Text] [Related]
55. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150 [TBL] [Abstract][Full Text] [Related]
56. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS]. Škunca Z; Planinc-Peraica A Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782 [TBL] [Abstract][Full Text] [Related]
57. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R; Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405 [TBL] [Abstract][Full Text] [Related]
58. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520 [TBL] [Abstract][Full Text] [Related]
59. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Iqbal J; Shen Y; Huang X; Liu Y; Wake L; Liu C; Deffenbacher K; Lachel CM; Wang C; Rohr J; Guo S; Smith LM; Wright G; Bhagavathi S; Dybkaer K; Fu K; Greiner TC; Vose JM; Jaffe E; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Armitage JO; Weisenburger DD; Staudt LM; Gascoyne RD; McKeithan TW; Chan WC Blood; 2015 Feb; 125(7):1137-45. PubMed ID: 25498913 [TBL] [Abstract][Full Text] [Related]
60. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]